Richard S. Finn, MD, Geffen School of Medicine

Articles

Evolving HCC Treatment Landscape: Combination Therapy

October 30th 2020

Developing Trial Regimens for Chinese Populations

October 30th 2020

High AFP as Deciding Factor for Treatment

October 30th 2020

Immunotherapy Monotherapy in Later-Line Setting

October 30th 2020

Second-Line Options After IMbrave150 Regimen

October 30th 2020

Promising Ongoing Frontline Trials

October 30th 2020

Importance of Endoscopy in Newly Diagnosed HCC

October 30th 2020

NCCN Guidelines: Nivolumab in Frontline Setting

October 30th 2020

Choosing a Frontline Therapy

October 30th 2020

Optimal HCC Frontline Treatments

October 30th 2020

The TACE Approach for Intermediate-Stage Disease

October 30th 2020

The BCLC Staging System

October 30th 2020

Screening Vs Diagnosis: Assessing Liver Function

October 30th 2020

The Complexity of HCC Multidisciplinary Management

October 30th 2020

Hepatocellular Carcinoma: A Rapidly Evolving Treatment Landscape

October 30th 2020

Discussion around topics pertaining to the use of systemic therapy in advanced liver cancer. Topics will include the latest research in the field and the impact of recent clinical trials on making decisions around treatment selection.

HCC: Applying Recent Data Into Practice

July 13th 2020

HCC: Emerging Therapies Under Investigation

July 13th 2020

Combination Regimens for HCC Treatment

July 13th 2020

Emerging Biomarkers in Hepatocellular Carcinoma

July 13th 2020

HCC: Liver Function and Treatment Decisions

July 13th 2020